Effect of Low Molecular Weight Heparin in Freeze-thaw Embryo Transfer Cycles in Women With Recurr… (NCT06991530) | Clinical Trial Compass
CompletedNot Applicable
Effect of Low Molecular Weight Heparin in Freeze-thaw Embryo Transfer Cycles in Women With Recurrent Implantation Failure
China392 participantsStarted 2021-01-01
Plain-language summary
Recurrent implantation failure (RIF) is considered a tough problem in assisted reproductive technology (ART) without effective treatments. The effect of low molecular weight heparin (LMWH) in pregnancy outcomes is controversial. In addition, there are few reports on the role of LMWH in population with RIF performing freeze-thaw embryo transfer (FET) cycles. The purpose of this study is to evaluate the effect of LMWH on pregnancy outcomes in women with FET cycles.
Who can participate
Age range
20 Years – 40 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women under or equal to the age of 40 when oocytes were retrieved;
* The history of at least 2 failed fresh embryo transfer/FET cycles and cumulative transfer of ≥ 3 high-quality embryos or cumulative transfer of ≥ 2 blastocysts;
* Planning to FET after IVF or ICSI cycles
Exclusion Criteria:
* Women with untreated hydrosalpinx, uterine cavity occupying lesions (uterine adhesions, submucous fibroids, endometrial polyps, et al.);
* Women with abnormal anatomical structure of uterus (unicornuate uterus, bipedal uterus, et al.);
* Women with endometrial thickness (EMT) \< 6mm on the day of transplantation;
* Women or their partner with abnormal chromosome karyotype (not including chromosome polymorphisms);
* Women with the history of recurrent spontaneous abortion (RSA);
* Women with a history of autoimmune or coagulation disorders;
* Women with contraindications to LMWH
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Ongoing pregnancy rate
Timeframe: from transplantation to delivery (assessed up to 40 weeks of gestation)